Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C

Mark Sulkowski, Curtis Cooper, Bela Hunyady, Jidong Jia, Pavel Ogurtsov, Markus Peck-Radosavljevic, Mitchell L. Shiffman, Cihan Yurdaydin, Olav Dalgard

Research output: Contribution to journalArticle

Abstract

HCV infects approximately 2-3% of the global population and is a leading cause of end-stage liver disease and hepatocellular carcinoma. Treatment of HCV infection with Peg-IFN in combination with ribavirin can eradicate HCV infection in 40-90% of patients; however, a major barrier to treatment uptake and delivery is the association of this therapy with frequent and, at times, serious adverse effects. Recognition and effective management of these adverse effects are critical components of the successful treatment of chronic HCV infection. In clinical trials, approximately 10-15% of patients discontinue Peg-IFN and ribavirin therapy due to adverse effects; however, in clinical practice, the rate of treatment discontinuation has been reported to be substantially higher. The off-target effect of Peg-IFN and ribavirin impacts most, if not all, organ systems; the most common adverse effects are hematologic, dermatologic, neurologic, immunologic, gastrointestinal, pulmonary, cardiovascular, and ocular. Regional and global variability exists in the nature of these adverse effects and the strategies employed to ameliorate their impact. This article provides a comprehensive literature review that systematically describes the adverse effects of Peg-IFN-α and ribavirin on various organ systems and, more importantly, recommends consensus approaches to managing those effects.

Original languageEnglish (US)
Pages (from-to)212-223
Number of pages12
JournalNature Reviews Gastroenterology and Hepatology
Volume8
Issue number4
DOIs
StatePublished - Apr 2011

Fingerprint

Ribavirin
Hepatitis C
Therapeutics
Infection
End Stage Liver Disease
Nervous System
Hepatocellular Carcinoma
Clinical Trials
Lung
Population

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. / Sulkowski, Mark; Cooper, Curtis; Hunyady, Bela; Jia, Jidong; Ogurtsov, Pavel; Peck-Radosavljevic, Markus; Shiffman, Mitchell L.; Yurdaydin, Cihan; Dalgard, Olav.

In: Nature Reviews Gastroenterology and Hepatology, Vol. 8, No. 4, 04.2011, p. 212-223.

Research output: Contribution to journalArticle

Sulkowski, M, Cooper, C, Hunyady, B, Jia, J, Ogurtsov, P, Peck-Radosavljevic, M, Shiffman, ML, Yurdaydin, C & Dalgard, O 2011, 'Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C', Nature Reviews Gastroenterology and Hepatology, vol. 8, no. 4, pp. 212-223. https://doi.org/10.1038/nrgastro.2011.21
Sulkowski, Mark ; Cooper, Curtis ; Hunyady, Bela ; Jia, Jidong ; Ogurtsov, Pavel ; Peck-Radosavljevic, Markus ; Shiffman, Mitchell L. ; Yurdaydin, Cihan ; Dalgard, Olav. / Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. In: Nature Reviews Gastroenterology and Hepatology. 2011 ; Vol. 8, No. 4. pp. 212-223.
@article{88fb091a85d14ade976baafd25bfa0b6,
title = "Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C",
abstract = "HCV infects approximately 2-3{\%} of the global population and is a leading cause of end-stage liver disease and hepatocellular carcinoma. Treatment of HCV infection with Peg-IFN in combination with ribavirin can eradicate HCV infection in 40-90{\%} of patients; however, a major barrier to treatment uptake and delivery is the association of this therapy with frequent and, at times, serious adverse effects. Recognition and effective management of these adverse effects are critical components of the successful treatment of chronic HCV infection. In clinical trials, approximately 10-15{\%} of patients discontinue Peg-IFN and ribavirin therapy due to adverse effects; however, in clinical practice, the rate of treatment discontinuation has been reported to be substantially higher. The off-target effect of Peg-IFN and ribavirin impacts most, if not all, organ systems; the most common adverse effects are hematologic, dermatologic, neurologic, immunologic, gastrointestinal, pulmonary, cardiovascular, and ocular. Regional and global variability exists in the nature of these adverse effects and the strategies employed to ameliorate their impact. This article provides a comprehensive literature review that systematically describes the adverse effects of Peg-IFN-α and ribavirin on various organ systems and, more importantly, recommends consensus approaches to managing those effects.",
author = "Mark Sulkowski and Curtis Cooper and Bela Hunyady and Jidong Jia and Pavel Ogurtsov and Markus Peck-Radosavljevic and Shiffman, {Mitchell L.} and Cihan Yurdaydin and Olav Dalgard",
year = "2011",
month = "4",
doi = "10.1038/nrgastro.2011.21",
language = "English (US)",
volume = "8",
pages = "212--223",
journal = "Nature Reviews Gastroenterology and Hepatology",
issn = "1759-5045",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C

AU - Sulkowski, Mark

AU - Cooper, Curtis

AU - Hunyady, Bela

AU - Jia, Jidong

AU - Ogurtsov, Pavel

AU - Peck-Radosavljevic, Markus

AU - Shiffman, Mitchell L.

AU - Yurdaydin, Cihan

AU - Dalgard, Olav

PY - 2011/4

Y1 - 2011/4

N2 - HCV infects approximately 2-3% of the global population and is a leading cause of end-stage liver disease and hepatocellular carcinoma. Treatment of HCV infection with Peg-IFN in combination with ribavirin can eradicate HCV infection in 40-90% of patients; however, a major barrier to treatment uptake and delivery is the association of this therapy with frequent and, at times, serious adverse effects. Recognition and effective management of these adverse effects are critical components of the successful treatment of chronic HCV infection. In clinical trials, approximately 10-15% of patients discontinue Peg-IFN and ribavirin therapy due to adverse effects; however, in clinical practice, the rate of treatment discontinuation has been reported to be substantially higher. The off-target effect of Peg-IFN and ribavirin impacts most, if not all, organ systems; the most common adverse effects are hematologic, dermatologic, neurologic, immunologic, gastrointestinal, pulmonary, cardiovascular, and ocular. Regional and global variability exists in the nature of these adverse effects and the strategies employed to ameliorate their impact. This article provides a comprehensive literature review that systematically describes the adverse effects of Peg-IFN-α and ribavirin on various organ systems and, more importantly, recommends consensus approaches to managing those effects.

AB - HCV infects approximately 2-3% of the global population and is a leading cause of end-stage liver disease and hepatocellular carcinoma. Treatment of HCV infection with Peg-IFN in combination with ribavirin can eradicate HCV infection in 40-90% of patients; however, a major barrier to treatment uptake and delivery is the association of this therapy with frequent and, at times, serious adverse effects. Recognition and effective management of these adverse effects are critical components of the successful treatment of chronic HCV infection. In clinical trials, approximately 10-15% of patients discontinue Peg-IFN and ribavirin therapy due to adverse effects; however, in clinical practice, the rate of treatment discontinuation has been reported to be substantially higher. The off-target effect of Peg-IFN and ribavirin impacts most, if not all, organ systems; the most common adverse effects are hematologic, dermatologic, neurologic, immunologic, gastrointestinal, pulmonary, cardiovascular, and ocular. Regional and global variability exists in the nature of these adverse effects and the strategies employed to ameliorate their impact. This article provides a comprehensive literature review that systematically describes the adverse effects of Peg-IFN-α and ribavirin on various organ systems and, more importantly, recommends consensus approaches to managing those effects.

UR - http://www.scopus.com/inward/record.url?scp=79953729036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953729036&partnerID=8YFLogxK

U2 - 10.1038/nrgastro.2011.21

DO - 10.1038/nrgastro.2011.21

M3 - Article

VL - 8

SP - 212

EP - 223

JO - Nature Reviews Gastroenterology and Hepatology

JF - Nature Reviews Gastroenterology and Hepatology

SN - 1759-5045

IS - 4

ER -